Michael Goren

Title: Michael Goren: Innovator in Eukaryotic Cell Technology

Introduction

Michael Goren is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of eukaryotic cells that incorporate adenovirus-associated virus polynucleotides. His work has implications for gene therapy and viral vector development.

Latest Patents

Michael Goren holds a patent for "Eukaryotic cells comprising adenovirus-associated virus polynucleotides." This invention provides eukaryotic cells, such as mammalian cells, that comprise adeno-associated virus (AAV) polynucleotides, including AAV capsid proteins (Cap). These cells are capable of expressing the polypeptides encoded by the AAV polynucleotides, thereby producing AAV, including recombinant AAV. The invention also includes methods for expressing AAV and adenovirus (Ad) polynucleotides in various eukaryotic cells, such as CHO cells, HEK 293, and BHK cells.

Career Highlights

Michael Goren is currently associated with Regeneron Pharmaceuticals, Inc., where he continues to advance his research in biotechnology. His innovative work has led to advancements in the understanding and application of viral vectors in therapeutic settings.

Collaborations

Some of his notable coworkers include Yu Zhao and Alexandros Strikoudis, who have collaborated with him on various projects within the field.

Conclusion

Michael Goren's contributions to the field of biotechnology, particularly through his patent on eukaryotic cells, highlight his role as an innovator in the industry. His work continues to influence advancements in gene therapy and viral vector technology.